Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rentosertib in Idiopathic Pulmonary Fibrosis
NCT07687459Phase 3Recruiting
- Sponsor
- Insilico Medicine
- Start
- Sep 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
A Phase 3 trial of INS018_055 in idiopathic pulmonary fibrosis (IPF), sponsored by Insilico Medicine. Started Sep 2026; status: recruiting.
02
Drugs
INS018_055
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07687459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07687459.